Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. on August 25, 2014. The report discloses the entry into a material definitive agreement regarding the commercialization of the Company's product, EXPAREL®.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment and does not contain financial performance data.
Material Changes
On August 25, 2014, the Company entered into a Second Amendment to its Commercial Outsourcing Services Agreement with Integrated Commercialization Solutions, Inc. (ICS). Key changes include:
- Extension of the agreement term to August 25, 2017.
- Updates to certain pricing terms.
- Confirmation that ICS remains the exclusive third-party logistics provider for EXPAREL® in the United States.
Outlook, Risks, and Management Commentary
The agreement continues to cover logistics services including customer support, warehousing, distribution, contract administration, chargeback processing, accounts receivable management, and IT services. The Company noted that the full text of the Second Amendment will be filed as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2014. No specific risks or contingencies were detailed in this filing beyond the standard qualification that the description is not complete.
Key Facts for Investor Verification
- Verify the specific pricing updates in the Second Amendment once filed as an exhibit to the Q3 2014 Form 10-Q.
- Confirm the impact of the extended logistics agreement on future operating expenses.
- Review the upcoming Form 10-Q for detailed financial performance metrics not included in this 8-K.